Matinas BioPharma Holdings, Inc Stock (NYSEAMERICAN:MTNB)

USA |NYSE MKT |USD

Price
$ 0.82
Change
-1.20%
Today's Range
$0.80 - $0.85
52-Week Range
$0.49 - $1.61
Market Cap
$173.49M
Volume
343.81K

About Matinas Biopharma Holdings, Inc (NYSEAMERICAN:MTNB)

(NYSEAMERICAN:MTNB) Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nano-crystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT9001, a prescription-only omega-3 free fatty acid formulation for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Neurological Disorders and Stroke (NINDS) for the development of a novel therapy for the treatment of HIV, as well as with ViiV Healthcare to develop and evaluate formulations of antiviral drug candidates; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was founded in 2013 and is based in Bedminster, New Jersey.
Show more

MTNB Stock Price

Statistics Highlights (NYSEAMERICAN:MTNB)

Shares Outstanding 216.86M Beta 2.22
Public Float 208.01M P/E Ratio -
% Short of Float - Dividend (Yield) -
Held by Insiders 2.92% Ex-Dividend Date
Held by Institutions 13.35% IPO Date Aug 18, 2014

MTNB Financial Summary

|
Dec 21 Dec 20 Dec 19
Revenue $33.00 $158.33K $89.81K
EBITDA $-23.95M $-21.67M $-16.59M
Net Income $-23.28M $-22.45M $-17.37M
Total Assets $61.33M $70.97M $40.24M
Total Cash $21.03M $12.43M $22.17M
Total Debt $5.24M $3.75M $4.23M
Dec 21 Sep 21 Jun 21
Revenue $-33.30K $0.00 $0.00
EBITDA $-6.51M $-6.68M $-4.61M
Net Income $-6.70M $-6.84M $-4.79M
Total Assets $61.33M $66.98M $69.97M
Total Cash $21.03M $24.92M $30.35M
Total Debt $5.24M $4.83M $3.51M

MTNB Stock Price History

Matinas Biopharma Holdings, Inc Annual Stock Price History

Year Open Close Change
2021 $1.03 $0.82 -20.39%
2021 $1.55 $1.03 -33.55%
2020 $2.19 $1.55 -29.22%

Matinas Biopharma Holdings, Inc Daily Stock Price History

Date Open High Low Close Change Volume
Jun 9, 2022 $0.83 $0.87 $0.83 $0.84 11.33% 283.90K
Jun 22, 2022 $0.73 $0.80 $0.73 $0.75 1.60% 289.13K
Jun 13, 2022 $0.82 $0.84 $0.74 $0.74 -4.05% 696.61K

(NYSEAMERICAN:MTNB) Stock Price FAQs

What is today's stock price of Matinas Biopharma Holdings, Inc (NYSEAMERICAN:MTNB)?

  • The current stock price of Matinas Biopharma Holdings, Inc (NYSEAMERICAN:MTNB) is $0.82.
  • Today MTNB stock price opened at $0.82 after previous close of $0.83.
  • During the day, Matinas Biopharma Holdings, Inc stock quote has varied from a low of $0.80 to a high of $0.85.

What is Matinas Biopharma Holdings, Inc's 52-week change?

  • MTNB 52-week high stock quote is $1.61, which is 96.30% above the current share price.
  • The Matinas Biopharma Holdings, Inc (NYSEAMERICAN:MTNB) 52-week low stock price is $0.49, which is 40.20% below the current share price.
  • Matinas Biopharma Holdings, Inc share price volatility (52-week beta) is 2.22.

Is Matinas Biopharma Holdings, Inc a buy?

  • According to 4 analysts, the current consensus recommendation for Matinas Biopharma Holdings, Inc stock is "Strong Buy" at an average rating score of 4.50 (out of 5).
  • There are currently 2 "Strong Buy", 2 "Buy", 0 "Hold", 0 "Sell", and 0 "Strong Sell" analysts recommendations for the MTNB stock.
  • The 12 month average price target forecast for MTNB stock is $2.75, representing a 235.40% increase from the current MTNB stock price of $0.82.

Matinas Biopharma Holdings, Inc (NYSEAMERICAN:MTNB) FAQ

How Much is Matinas biopharma holdings, inc Worth?

Matinas biopharma holdings, inc's worth today based on market capitalisation is $173.49M

How much dividend does Matinas biopharma holdings, inc Pay?

The current annualized dividend payout for MTNB stock is $0.00, the dividend yield is 0.00% and the payout ratio is 0.00%.
View More Details on Matinas biopharma holdings, inc's "Dividend" Section

When is the next earnings date for Matinas biopharma holdings, inc (NYSEAMERICAN:MTNB)?

Matinas biopharma holdings, inc is expected to report earnings on November 07 ,2022.
View More Details on Matinas biopharma holdings, inc's 'Earnings' Section

What is Matinas biopharma holdings, inc’s Price to Earning (PE) ratio?

MTNB stock also has a Price to Sales (P/S) ratio of 5204.81, a Price to Book of 3.49 and Price/Earnings to Growth (PEG) of 0.00.

What is the Matinas biopharma holdings, inc's ticker?

Matinas biopharma holdings, inc trades on the NYSE American stock market in USA under the ticker symbol "MTNB". Matinas biopharma holdings, inc’s stock symbol can also be displayed as "NYSEAMERICAN:MTNB".

When did MTNB go public?

Matinas biopharma holdings, inc completed its initial public offering (IPO) on August 18 ,2014.

Who are the owners of Matinas biopharma holdings, inc?

Matinas biopharma holdings, inc (NYSEAMERICAN:MTNB) is owned by 13.35% institutional shareholders and by 2.92% insiders. The rest is owned by the public.
Explore More Details on Matinas biopharma holdings, inc's “Ownership” Section

Who are the key executives of Matinas biopharma holdings, inc (MTNB)?

Matinas biopharma holdings, inc's key executive team includes the following managers:

  • Mr. Jerome D. Jabbour J.D., Co-Founder, CEO, Pres & Director (1974)
  • Dr. Theresa Matkovits Ph.D., Chief Devel. Officer (1967)
  • Dr. James J. Ferguson FACC, M.D., Chief Medical Officer (1955)
  • Mr. Keith A. Kucinski CPA, M.B.A., Chief Financial Officer (1970)
  • Dr. Hui Liu M.B.A., Ph.D., Chief Technology Officer (1968)
  • Dr. Raphael J. Mannino Ph.D., Chief Scientific Officer (1947)
  • Mr. Frank Calamusa, Exec. Director and Head of Manufacturing & Supply Chain (NA)
  • Mr. Thomas J. Hoover M.B.A., Chief Bus. Officer (1970)

What is Matinas biopharma holdings, inc’s Sector & Industry Classification?

Matinas biopharma holdings, inc (NYSEAMERICAN:MTNB) is classified under the "Healthcare" sector and under the "Biotechnology" industry.

How many employees work for Matinas biopharma holdings, inc?

Currently the number of employees working for Matinas biopharma holdings, inc is 31.

Where are Matinas biopharma holdings, inc's Headquarters?

Matinas biopharma holdings, inc (NYSEAMERICAN:MTNB) is headquartered in NJ, United States.

What are Matinas biopharma holdings, inc's Address and Phone Number?

Matinas biopharma holdings, inc’s mailing address is 1545 Route 206 South, Bedminster, NJ, United States, 07921.
The company’s phone number is 908 484 8805.

What is the official website for Matinas biopharma holdings, inc?

Matinas biopharma holdings, inc’s official website is http://www.matinasbiopharma.com